This independent CME activity is
supported by an educational grant from GlaxoSmithKline.
Candice E. Johnson, MD, PhD
Clinical Professor of Pediatrics
Department of Pediatrics
The Children's Hospital
University of Colorado
School of Medicine
Denver, CO
Ronald N. Jones, MD
President/CEO
JMI Laboratories
North Liberty, IA
John E. McGowan, Jr, MD
Professor, Department
of Epidemiology
Rollins School of Public Health
Emory University
Atlanta, GA
Lawrence C. Parish, MD
Clinical Professor of
Dermatology and
Cutaneous Biology
Director of the Jefferson
Center for International
Dermatology
Jefferson Medical College
of Thomas Jefferson
University
Philadelphia, PA
Statement of Accreditation
Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge designates each audio presentation in this 4-part series for .25 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This activity is planned and implemented as an independent CME activity in accordance with the ACCME Essential Areas and Policies.
Earn 1 credit for completing the entire 4-part series.
Estimated time for completion of this activity: 1 hour (15 minutes for each posting)
The goal of this activity is to educate clinicians about all aspects of uncomplicated skin and skin structure infections and their treatment with various agents, and with methods for minimizing the development of resistance, leading to improved patient outcomes.
This CME activity is designed for pediatricians and pediatric dermatologists.
Apply knowledge of prevalence, risk factors, and typical history of pediatric uSSSIs to help prevent and identify uSSSIs in at-risk children.
Assess and determine when to hospitalize a child with an invasive skin infection in order to properly treat these infections.
Using knowledge of the process by which selective pressure and gene action result in the development of antibiotic resistance and cross-resistance, construct treatment strategies that minimize the risk of resistance in pediatric patients with uSSSIs.
Demonstrate appropriate local care of topical wounds, including proper skin care and implementation of topical antibiotics when appropriate, in order to promote rapid and effective wound healing.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest
quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, please click here.
The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed.
For complete prescribing information on the products discussed during this CME activity, please see your current Physicians’ Desk Reference (PDR).
Candice E. Johnson, MD, PhD, has received grant/research support from Ferndale Labs, GlaxoSmithKline, and Merck & Co, Inc; is a consultant for Merck & Co, Inc; and is on the speakers bureau for Abbott Laboratories, GlaxoSmithKline, and Merck & Co, Inc.
Dr. Johnson has disclosed that she will not reference unlabeled or unapproved uses of drugs or devices.
Ronald N. Jones, MD, has received grant/research support from AB Biodisk, Abbott Laboratories, AlamX, Arpida, AstraZeneca Pharmaceuticals LP, Avexa, Basilea Pharmaceuticals, Bayer Pharmaceuticals, Becton Dickinson, BioMerieux, Bristol-Myers Squibb, Cadence Pharmaceuticals, Cerexa, Chiron Corporation, Cognigen, Cubist Pharmaceuticals, Daiichi, Elan Pharmaceuticals, Elanco, Enanta, GlaxoSmithKline, Intrabiotics, Johnson & Johnson, LG Chemicals, Merck & Co, Inc, Micrologix, Novartis Pharmaceuticals Corporation, Optimer, Ordway, Oscient Pharmaceuticals, Osmotics, Peninsula, Pfizer Inc, Replidyne, Inc, Schering-Plough Corporation, Sequoia, Serenex, Shionogi, Theravance, TREK Diagnostic Systems, Vicuron Pharmaceuticals, and Wyeth Pharmaceuticals. Dr. Jones has disclosed that he will not reference unlabeled/unapproved uses of drugs or devices.
John E. McGowan, Jr, MD, has received grant/research support from AstraZeneca Pharmaceuticals, LP, BioMerieux, Elan Pharmaceuticals, 3M Health Care, and Pfizer Inc; and is a consultant for Cubist Pharmaceuticals, Dade Behring Inc, Elan Pharmaceuticals, Johnson & Johnson, Merck & Co, Inc, Replidyne, Inc, and Wyeth Pharmaceuticals. Dr. McGowan has disclosed that he will not reference unlabeled/unapproved uses of drugs or devices.
Lawrence C. Parish, MD, is a consultant for CollaGenex Pharmaceuticals and Quinnova Pharmaceuticals. Dr. Parish has disclosed that he will not reference unlabeled/unapproved uses of drugs or devices.
Peer Reviewer has no significant relationships to disclose.
Projects In Knowledge's staff members have no significant relationships to disclose.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Click here to view the technical requirements necessary for participation.
Get iTunes.
If you are experiencing any difficulty with this CME activity, please contact us.
Editorial developed by
Projects In Knowledge, Inc.
Copyright © 2006-2012
|
Projects In Knowledge, Inc.
Overlook at Great Notch
150 Clove Road
Little Falls,
New Jersey 07424
Tel: (973) 890-8988
Fax: (973) 890-8866 |
|
Part 4
LEARNING OBJECTIVE: Demonstrate appropriate local care of topical wounds, including proper skin care and implementation of topical antibiotics when appropriate, in order to promote rapid and effective wound healing.
Length: 15:54
Est. download time 56k: 10 min., Broadband: 2 min.
Lawrence C. Parish, MD
Listen to the fourth podcast, which focuses on the topical treatment of bacterial skin infections.
In this fourth and final installment of Newsmakers In Medicine, the Infectious Diseases Edition, Dr. Lawrence C. Parish, Clinical Professor of Dermatology and Cutaneous Biology at the Jefferson Medical College of Thomas Jefferson University, Philadelphia, discusses which skin infections are amenable to topical treatment.
Dr. Parish notes that the increased incidence of community-acquired methicillin-resistant Staphylococcus aureus (MRSA) poses a problem for the office dermatologist. Culturing is now more important, but managed care sometimes dictates that cultures be sent to distant laboratories, so results are not always dependable. Therefore, the coverage afforded by empiric therapy is an important consideration.
Specifically, Dr. Parish addresses the following questions:
- How useful is topical therapy for infected skin lesions in the outpatient setting?
- Does every infection require a culture?
- How important are incision and drainage?
- Is the utility of mupirocin being compromised by resistance?
- How has the increasing incidence of MRSA affected your choice of initial empiric therapy—systemic and topical?
- The cardinal principle of medical treatment is "First, do no harm." Can you relate this tenet specifically to over-the-counter topical therapies? Which topical therapies would you NOT recommend?
Release Date: January 19, 2007.
Termination Date: January 19, 2008.
Estimated time for completion: 15 minutes.
Lawrence C. Parish, MD, is a consultant for CollaGenex Pharmaceuticals and Quinnova Pharmaceuticals. Dr. Parish has disclosed that he will not reference unlabeled/unapproved uses of drugs or devices.
Top
Part 3
LEARNING OBJECTIVE: Using knowledge of the process by which selective pressure and gene action result in the development of antibiotic resistance and cross-resistance, construct treatment strategies that minimize the risk of resistance in pediatric patients with uSSSIs.
Length: 19:17
Est. download time 56k: 10 min., Broadband: 2 min.
Ronald N. Jones, MD
Listen to the third podcast, which focuses on resistance in Staphylococcus aureus, the predominant pathogen in skin and skin structure infections.
In the third installment of Newsmakers In Medicine, the Infectious Diseases Edition, Dr. Ronald N. Jones, President/CEO of JMI Laboratories, North Liberty, Iowa, discusses the evolution of staphylococccal resistance over the past 35 years.
Dr. Jones notes that the incidence of methicillin-resistant S. aureus was very low in the 1970s but has been rising steadily in both the hospital and community settings. However, this increased incidence is not uniformly observed: it varies not only between countries but also regionally within the United States. Because S. aureus has always been the greatest single burden of infection, this is of great concern.
Specifically, Dr. Jones addresses the following questions:
- What has the SENTRY project shown about the increasing incidence of MRSA in the community?
- Do you see methicillin resistance becoming as widespread as beta-lactamase resistance?
- How do methicillin resistance rates vary across the United States and Canada?
- How do community strains of MRSA differ from hospital-acquired S. aureus?
- Is MRSA the Andromeda strain?
- Can resistance to antibiotics that are currently effective against MRSA be minimized by the concurrent use of effective topical therapy?
Release Date: January 9, 2007.
Termination Date: January 9, 2008.
Estimated time for completion: 15 minutes.
Ronald N. Jones, MD, has received grant/research support from AB Biodisk, Abbott Laboratories, AlamX, Arpida, AstraZeneca Pharmaceuticals LP, Avexa, Basilea Pharmaceuticals, Bayer Pharmaceuticals, Becton Dickinson, BioMerieux, Bristol-Myers Squibb, Cadence Pharmaceuticals, Cerexa, Chiron Corporation, Cognigen, Cubist Pharmaceuticals, Daiichi, Elan Pharmaceuticals, Elanco, Enanta, GlaxoSmithKline, Intrabiotics, Johnson & Johnson, LG Chemicals, Merck & Co, Inc, Micrologix, Novartis Pharmaceuticals Corporation, Optimer, Ordway, Oscient Pharmaceuticals, Osmotics, Peninsula, Pfizer Inc, Replidyne, Inc, Schering-Plough Corporation, Sequoia, Serenex, Shionogi, Theravance, TREK Diagnostic Systems, Vicuron Pharmaceuticals, and Wyeth Pharmaceuticals. Dr. Jones has disclosed that he will not reference unlabeled/unapproved uses of drugs or devices.
Top
Part 2
LEARNING OBJECTIVE: Assess and determine when to hospitalize a child with an invasive skin infection in order to properly treat these infections.
Length: 14:35
Est. download time 56k: 10 min., Broadband: 2 min.
Candice E. Johnson, MD, PhD
Listen to the second podcast, which focuses on the diagnosis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in pediatric patients.
In this second installment of Newsmakers In Medicine, the Infectious Diseases Edition, Dr. Candice E. Johnson, Clinical Professor of Pediatrics at the University of Colorado School of Medicine and The Children's Hospital, Denver, discusses how pediatric practice has been impacted by the tremendous increase in methicillin resistance.
Dr. Johnson observes that cultures are being done more frequently now, so susceptibility results can guide treatment should initial empiric therapy fail. The predominance of methicillin resistance in some areas also has limited pediatricians' therapeutic choices.
Specifically, Dr. Johnson addresses the following questions:
- How does bacterial resistance in the pathogens responsible for uSSSIs affect your choice of empiric therapy?
- Has the increasing incidence of CA-MRSA led the doctors in your area to do more culturing of skin and skin structure infections?
- Is failure of initial antibiotic therapy becoming more common?
- Since there are few oral agents available that cover both MRSA and group A S. pyogenes (for example, clindamycin), are you also prescribing topical therapy?
- Has the effectiveness of mupirocin been compromised by increasing resistance? Does the pleuromutilin class of antibiotics hold promise for more effective topical treatment?
- What are the IDSA guidelines for treatment of MRSA, and what new agents have become available since these guidelines were formulated?
- When do you hospitalize children with SSSIs?
- In addition to site of the infection, what other factors determine treatment decisions?
Release Date: December 15, 2006.
Termination Date: December 15, 2007.
Estimated time for completion: 15 minutes.
Candice E. Johnson, MD, PhD, has received grant/research support from Ferndale Labs, GlaxoSmithKline, and Merck & Co, Inc; is a consultant for Merck & Co, Inc; and is on the speakers bureau for Abbott Laboratories, GlaxoSmithKline, and Merck & Co, Inc. Dr. Johnson has disclosed that she will not reference unlabeled or unapproved uses of drugs or devices.
Top
Part 1
LEARNING OBJECTIVE: Apply knowledge of prevalence, risk factors, and typical history of pediatric uSSSIs to help prevent and identify uSSSIs in at-risk children.
Length: 13:28
Est. download time 56k: 10 min., Broadband: 2 min.
John E. McGowan, Jr, MD
Listen to the first podcast, which focuses on the epidemiology of methicillin-resistant Staphylococcus aureus (MRSA).
In this first installment of Newsmakers In Medicine, the Infectious Diseases Edition, Dr. John E. McGowan, Jr, Professor of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, discusses the changing etiology of pediatric skin and skin structure infections. Dr. McGowan notes that the predominance of methicillin-resistant Staphylococcus aureus strains in many parts of the country has rendered many formerly useful beta-lactam antibiotics ineffective. Empiric prescribing is still possible, but follow-up is vital.
Specifically, Dr. McGowan addresses the following questions:
- What can you tell us about the changing etiology of skin and skin structure infections—specifically, the shift in the predominance of resistant Gram-positive pathogens?
- What kinds of problems are caused by the emergence of community-associated MRSA?
- Which outpatient populations are most at risk for resistant S. aureus infections?
- Are community-acquired MRSA strains more virulent than those from the healthcare setting?
- Is it important to consider spread of community-acquired MRSA to family members? What measures can be taken to prevent outbreaks of MRSA in family members of patients with skin and skin structure infections? Are there some preventive measures one can take to decrease the spread of MRSA in the healthcare setting?
Release Date: December 1, 2006.
Termination Date: December 1, 2007.
Estimated time for completion: 15 minutes.
John E. McGowan, Jr, MD, has received grant/research support from AstraZeneca Pharmaceuticals, LP, BioMerieux, Elan Pharmaceuticals, 3M Health Care, and Pfizer Inc; and is a consultant for Cubist Pharmaceuticals, Dade Behring Inc, Elan Pharmaceuticals, Johnson & Johnson, Merck & Co, Inc, Replidyne, Inc, and Wyeth Pharmaceuticals. Dr. McGowan has disclosed that he will not reference unlabeled/unapproved uses of drugs or devices.
Top
1784
|
This 4-part series on uncomplicated skin and skin structure infections features discussions on:
- Growing prevalence of methicillin-resistant Staphylococcus aureus infection in the community
- Current practices in culturing and empiric prescribing
- Factors contributing to resistance
- When topical treatment may be appropriate
The podcasts are available as streaming audio or can be downloaded to a computer or MP3 player. Earn CME credit by taking the posttest for each podcast.
Estimated time for completion of this activity: 1 hour (15 minutes for each posting).
CME Instructions:
To receive CME credit for your participation in this CME activity,
please complete the following steps:
- Participate in this online activity by listening to any or all of the audio podcasts.
- Complete the CME Posttest following each podcast, selecting the most appropriate response to each question.
- Complete the CME Evaluation.
- Instantly access and print out your certificate.
|
|
